IP Library Granted Patent US 11,378,570
Granted Patent B2
US 11,378,570 · App. 15/988,421 · Granted Jul 5, 2022

Cytotoxicity test method for medical devices

Inventors: Xuemei Liu (Fort Worth, TX); Fan Zhang (Keller, TX); Denise P. Rodeheaver (Fort Worth, TX); Ann Marie Wright (Roswell, GA); Charlon Tolliver (Fort Worth, TX); Jamie Michaelis Walker (Burleson, TX); Robert Edward Rose (North Richland Hills, TX); Stephen Paul Shannon (Arlington, TX); Jeffrey Charles White (Southlake, TX)
Assignee: Alcon Inc.
G01N33/5014G01N15/00C12M1/34C12M23/12C12M41/36C12M41/46C12N5/0634
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,378,570
App. No.
15/988,421
Granted
Jul 5, 2022
Kind
B2
Abstract

A cytotoxicity method for medical devices that has equivalent sensitivity, and greater efficiency compared to the colony formation assay (CFA) direct contact method is developed. The quantitative, direct contact cytotoxicity test method uses Mouse lymphoma TK or human lymphoblastoid TK6 suspension cells for medical device safety assessment. The advantages of using the suspension cell assay over adherent V79-4 cells is that this approach is quantitative, automated, not susceptible to potential mechanical damage imparted by the overlying test materials, and avoids issues related to non-adherence of cells to the test material which might impact the interpretation of test results.

Claims (13)

1. A method of quantifying the cytotoxicity of a medical device, the method comprising: a) providing a medical device; b) incubating the medical device with suspension cells in culture medium for growing the suspension cells; c) taking the images of the cells, d) determining the quantity of living cells using a cell counter with image analysis, wherein the suspension cells are mouse lymphoma thymidine kinase (TK) or human lymphoblastoid lymphoma thymidine kinase 6 (TK6) cells.

2. The method of claim 1 , wherein the suspension cells are Mouse lymphoma TK cells.

3. The method of claim 1 , wherein a reagent of the culture medium is select from a group consisting of heat-deactivated horse serum, sodium pyruvate, a non-ionic surfactant with a polyoxypropylene molecular mass of 1800 g/mol and a 80% polyoxyethylene content (pluronic F68) and combination thereof.

4. The method of claim 1 , wherein the step of d) determining the quantity of living cells is to use a cell counter with image analysis cells based on the cell size, circularity, brightness, or shape.

5. The method of claim 1 , further comprising the steps of labeling the cells with a dye.

6. The method of claim 5 , further comprising the steps of detecting the labelled cells.

7. The method of claim 6 , wherein the incubating in step (b) is effected in a 6, 24 or 96-multi-well plate.

8. The method of claim 5 , wherein the dye is Trypan Blue.

9. The method of claim 1 , wherein the incubating in step (b) is effected in a multi-well plate.

10. The method of claim 1 , wherein the medical device is a contact lens.

11. The method of claim 1 , wherein the medical device is a stent.

12. The method of claim 1 , wherein the medical device is a scaffold.

13. The method of claim 1 , wherein the medical device is an implant.

Assignments (3)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2018
From: LIU, XUEMEI; ZHANG, FAN; RODEHEAVER, DENISE P.; WRIGHT, ANN MARIE; TOLLIVER, CHARLON; WALKER, JAMIE MICHAELIS; ROSE, ROBERT EDWARD; SHANNON, STEPHEN PAUL; WHITE, JEFFREY CHARLES
To: ALCON RESEARCH, LTD
Reel/Frame 047310/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2018
From: ALCON RESEARCH LTD.
To: NOVARTIS AG
Reel/Frame 047310/0720 →